Home > Tetraphase Pharmaceuticals Salary

Tetraphase Pharmaceuticals Salary

  • 77
  • 57
  • 31
Tetraphase Pharmaceuticals average salary is $176,423, median salary is $176,423 with a salary range from $176,423 to $176,423.
Tetraphase Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. Tetraphase Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 1 Tetraphase Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Tetraphase Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Tetraphase Pharmaceuticals Jobs
See more Tetraphase Pharmaceuticals Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Patents information
272

All Patents

71

Grant Patents

149

Patents Pending

43

Patents Families

More Recent
Tetraphase Pharmaceuti... Information
  • Tetraphase Pharmaceuticals
  • Industry: BioTech/Drugs
  • City: Watertown, MA
  • Tetraphase Pharmaceuticals was established in 2006 to advance and commercialize breakthrough synthetic chemistry developed by world-leading organic chemist Professor Andrew G. Myers, Ph.D., Chair, Department of Chemical Biology at Harvard University. This ground-breaking and transformational advance in chemistry, the Myers process, provides the company with a broad-range of commercial opportunities across a number of significant disease categories. The Company¡¯s initial focus is on the discovery and development of novel antibiotics to treat drug-resistant infections. This enabling technology also provides meaningful opportunities in inflammation and cancer.